Annual general meeting 2021 of Cell Impact

Cell Impact AB's (Nasdaq First North GM: CI B) annual general meeting for the financial year 2020 was held on 22 April, 2021.

Due to the Covid-19 pandemic and the restrictions introduced to prevent the spread of the virus, the annual general meeting was conducted by postal vote, without physical attendance.

Adoption of the profit and loss account and balance sheet as well as profit allocation

The annual general meeting approved the balance sheets and income statements included in the annual report for the financial year 2020 and resolved, in accordance with the proposal of the board of directors and the CEO, that available profits of SEK 187,959,798 should be carried forward.

Board of directors and auditor

The annual general meeting granted the directors of the board and the CEO discharge from liability for the financial year 2020.

The annual general meeting resolved that the board shall consists of five ordinary board members without deputies. The annual general meeting re-elected Robert Sobocki, Thomas Carlström and Anna Frick and elected Mattias Silfversparre and Mikael Eurenius as board members for the period until the end of the next annual general meeting. Robert Sobocki was re-elected chairman of the board. The annual general meeting further resolved to re-elect the registered auditing company PricewaterhouseCoopers AB as auditor for the period until the end of the next annual general meeting. The authorized public accountant Gert-Ove Levinsson will be the main responsible auditor.

Remuneration to the board members and the auditor

The annual general meeting approved that board fees shall be paid in the amount of SEK 300,000 to the chairman and SEK 150,000 to each of the other board members elected by the annual general meeting for the period until the end of the next annual general meeting. Furthermore, the board shall have the right to decide on renumeration to a board member of SEK 8,000 per day for consulting work performed that is not covered by customary board work. The annual general meeting resolved that fees to the auditor shall be paid on an ongoing basis in accordance with invoices approved by the company.

Nomination committee

The annual general meeting re-elected Mattias Klintemar and the company's chairman of the board and elected Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee. Furthermore, the annual general meeting resolved on guidelines for the nomination committee.

Incentive program for senior executives and other co-workers

The annual general meeting resolved to introduce an incentive program through a directed issue of a maximum of 530,000 warrants to the wholly owned subsidiary Finshyttan Hydropower AB and to approve the subsidiary's transfer of the warrants to the CEO, other senior executives in the company and other co-workers in the group. The warrants shall be transferred on market conditions at a price determined on the basis of a calculated market value for the warrants using the Black & Scholes valuation model. Each warrant entitles the holder to subscribe for one (1) class B share in the company and can be exercised during the period from and including 3 June 2024 to and including 2 July 2024. The subscription price per class B share shall correspond to 200 percent of the volume-weighted average price according to Nasdaq First North Growth Markets' official price list for the share during the period of ten trading days immediately after 12 May 2021.

Authorization for the board of directors to decide upon issue of shares, warrants and/or convertibles

The board's proposal on authorization for the board of directors to decide upon issue of shares, warrants and/or convertibles did not receive a sufficient majority and was therefore not voted through by the annual general meeting.

Amendments of the articles of association

The annual general meeting resolved on amendments of the articles of association, e.g. including the following: The object was adjusted so that the company shall develop, manufacture and market flow plates for use primarily in the fuel cell and hydrogen industry and conduct operations compatible therewith. A new section was added which gives the board the right to collect proxies in accordance with Chapter 7 Section 4 second paragraph of the Swedish Companies Act and decide that the shareholders shall be able to exercise their voting rights by post in accordance with Chapter 7 Section 4 a of the Swedish Companies Act.

For more detailed information on the content of the resolutions, please see the notice convening the annual general meeting and the complete proposals, which are available on the company's website www.cellimpact.com.

For more information, please contact:

Mr. Pär Teike, CEO, +46 73-024 06 84 or [email protected].

About Cell Impact

Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique method for high-velocity forming, Cell Impact Forming, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company's Certified Advisor (CA). Contact info: +46 8-528 00 399 or [email protected].

Styrelsen i Cell Impact har beslutat om en fullt garanterad företrädesemission om upp till cirka 349 miljoner kronor

Styrelsen i Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") har idag, med stöd av bemyndigandet lämnat av extra bolagstämma den 16 november 2021, beslutat om en fullt garanterad företrädesemission om högst 16 812 094 B-aktier med företrädesrätt för Bolagets befintliga aktieägare ("Företrädesemissionen"). Teckningskursen i Företrädesemissionen är 20,75 kronor per B-aktie. Om Företrädesemissionen fulltecknas kommer Bolaget tillföras cirka 349 miljoner kronor före avdrag för transaktionskostnader relaterade till Företrädesemissionen.


The Board of Directors in Cell Impact has resolved on a fully guaranteed rights issue of up to approximately SEK 349 million

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on November 16, 2021, resolved on a fully guaranteed rights issue of up to 16,812,094 series B shares with preferential right for the Company's existing shareholders (the "Rights Issue"). The subscription price in the Rights Issue is SEK 20.75 per series B share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.


Uppdaterad indikativ tidplan för Cell Impacts fullt garanterade företrädesemission

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") meddelar idag en uppdaterad indikativ tidplan för den fullt garanterade Företrädesemissionen. Den uppdaterade indikativa tidplanen avviker från den tidigare kommunicerade indikativa tidplanen då planerat prospektgodkännande har senarelagts på grund av hög arbetsbelastning hos Finansinspektionens prospektenhet.


Updated indicative timetable for Cell Impact's fully guaranteed rights issue

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces an updated indicative timetable for the fully guaranteed Rights Issue. The updated indicative timetable deviates from the previously communicated indicative timetable due to a postponed prospectus approval as a result of high workload for the Swedish Financial Supervisory Authority's prospectus unit.


Kommuniké från extra bolagsstämma i Cell Impact

Extra bolagstämma i Cell Impact AB (publ) hölls den 16 november 2021 varvid aktieägarna bland annat fattade beslut om emissionsbemyndigande.


Extraordinary general meeting of Cell Impact

An extraordinary general meeting of Cell Impact AB (publ) was held on 16 November 2021 whereby the shareholders, inter alia, authorized the board of directors to resolve upon issue of shares, warrants and/or convertibles.


Kallelse till extra bolagsstämma i Cell Impact

Aktieägarna i Cell Impact AB (publ), org.nr 556576-6655, kallas härmed till extra bolagsstämma tisdagen den 16 november 2021.


Notice of extraordinary general meeting of Cell Impact

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Tuesday 16 November 2021.


Styrelsen i Cell Impact avser att besluta om en fullt garanterad företrädesemission om upp till cirka 350 miljoner kronor

Styrelsen i Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") meddelar idag sin avsikt att besluta om en fullt garanterad företrädesemission av B-aktier om upp till cirka 350 miljoner kronor ("Företrädesemissionen"). En extra bolagsstämma föreslås besluta om ett emissionsbemyndigande, med stöd av vilket Bolagets styrelse avser att besluta om Företrädesemissionen. Bolagets extra bolagsstämma planeras att hållas den 16 november 2021 och kallelsen kommer att publiceras genom ett separat pressmeddelande. Syftet med Företrädesemissionen är att säkerställa fortsatt finansiering av Cell Impacts affärsplan med tillhörande ökning av Bolagets produktionskapacitet. Tillsammans med befintlig kassa förväntas nettolikviden från Företrädesemissionen vara tillräcklig för att finansiera Bolagets affärsplan till mitten av 2023 förutsatt att Företrädesemissionen inbringar en bruttolikvid om cirka 350 miljoner kronor.


The Board of Directors in Cell Impact intends to resolve on a fully guaranteed rights issue of up to approximately SEK 350 million

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces its intention to resolve on a fully guaranteed rights issue of series B shares of up to approximately SEK 350 million (the "Rights Issue"). An Extra General Meeting is proposed to authorize the Board of Directors to resolve on the Rights Issue. The Extra General Meeting intends to be held on November 16, 2021 and the notice will be announced through a separate press release. The purpose of the Rights Issue is to ensure continued financing of Cell Impact's business plan, which includes increasing the Company's production capacity. Together with existing cash, the net proceeds from the Rights Issue is expected to be sufficient to finance the Company's business plan to mid-2023 provided that the Rights Issue generates gross proceeds of approximately SEK 350 million.


Cell Impact delårsrapport för tredje kvartalet: Fortsatt stark tillväxt

Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för tredje kvartalet.


Cell Impact reports third quarter results: Continued strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the third quarter.




Cell Impact förstärker ledningen med ny HR-chef

Cell Impact AB (Nasdaq First North GM: CI B) meddelar att Karina Sick Larsson har utsetts till Chief Human Resources Officer (CHRO) med tillträdesdag 16 september 2021. Karina kommer ansvara för bolagets HR-funktion med fokus kompetensutveckling.


Cell Impact strengthens management with new CHRO

Cell Impact AB (Nasdaq First North GM: Cell Impact AB (Nasdaq First North GM: CI B) is pleased to announce that Karina Sick Larsson has been appointed as Chief Human Resources Officer (CHRO) and will start her position on September 16, 2021. Karina will be responsible for the company's human resources function with a focus on organizational development.


Cell Impact delårsrapport för andra kvartalet 2021: Stark tillväxt

Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för första kvartalet.


Cell Impact reports second quarter results for 2021: Strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.


Kommuniké från extra bolagstämma i Cell Impact AB

Extra bolagstämma i Cell Impact AB (Nasdaq First North GM: CI B) hölls den 9 augusti 2021.


Extraordinary general meeting of Cell Impact AB

An extraordinary general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on August 9, 2021.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted